LEGN Stock Summary and Trading Ideas (Legend Biotech - American Depositary Shares | NASDAQ:LEGN)

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.

As of March 31, 2026, LEGN stock price climbed to $17.94 with 705,860 million shares trading.

LEGN has a beta of 0.62, meaning it tends to be less sensitive to market movements. LEGN has a correlation of 0.05 to the broad based SPY ETF.

LEGN has a market cap of $3.29 billion. This is considered a Mid Cap stock.

Last quarter Legend Biotech - American Depositary Shares reported $306 million in Revenue and $.01 earnings per share. This beat revenue expectation by $268,766 and exceeded earnings estimates by $.19.

In the last 3 years, LEGN traded as high as $77.32 and as low as $16.24.

The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, MCHI, CANC, EEM.

LEGN has underperformed the market in the last year with a price return of -48.8% while the SPY ETF gained +17.9%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.7% and -6.1%, respectively, while the SPY returned -5.5% and -2.9%, respectively.

LEGN support price is $16.74 and resistance is $17.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.